Name a risk associated with the use of SSRIs during pregnancy.

The use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy has been studied for various potential risks, and one significant concern is the possible association with congenital malformations. Some research indicates that exposure to SSRIs during the first trimester may increase the risk of certain birth defects, particularly those related to the cardiac system. This risk stems from the understanding that serotonin plays important roles in fetal development, and alterations in serotonin levels due to SSRIs may affect the normal processes of organogenesis.

In contrast, while there are concerns related to premature birth and growth rates, these factors do not directly correlate to the more established evidence linking SSRIs to structural malformations in developing fetuses. Improved fetal development is not a recognized risk associated with SSRI use in pregnancy. Therefore, the focus on congenital malformations as a risk emphasizes the importance of carefully weighing the benefits and risks of using SSRIs during this critical period.